论文部分内容阅读
目的探讨NSCLC组织中棘皮动物微管样蛋白4-间变淋巴瘤激酶(EML4-ALK)融合基因与切除修复交叉互补蛋白1(ERCC1)和核苷酸还原酶亚单位M1(RRM1)mRNA表达的关系。方法应用实时荧光定量PCR方法检测257例NSCLC组织中EML4-ALK基因以及ERCC1和RRM1 mRNA的表达。结果 NSCLC组织中EML4-ALK融合基因阳性率占4.28%(11/257),在不吸烟患者中较高(P<0.05);ERCC1 mRNA高表达占47.47%(122/257),RRM1 mRNA高表达占61.87%(159/257)。与未检测到EML4-ALK融合基因阳性的NSCLC患者比较,EML4-ALK融合基因阳性与ERCC1 mRNA表达水平无关(P>0.05);NSCLC组织中,EML4-ALK融合基因阳性与RRM1 mRNA表达水平无关(P>0.05);但ERCC1mRNA表达水平与RRM1 mRNA表达水平相关(P<0.05)。结论 NSCLC组织中EML4-ALK融合基因阳性患者不能从以铂类和他滨类一线化疗药中获益,因此仍需进一步探索更有效的个体化治疗方案,特别是对EML4-ALK融合基因选择性抑制剂克唑替尼原发或继发耐药部分患者的个体化治疗方案。
Objective To investigate the expression of ERCC1 and RRM1 mRNA in echinoderm-like microtubule-like protein 4-anaplastic lymphoma kinase (EML4-ALK) in NSCLC tissues relationship. Methods The expression of EML4-ALK gene and ERCC1 and RRM1 mRNA in 257 NSCLC tissues were detected by real-time fluorescence quantitative PCR. Results The positive rate of EML4-ALK fusion gene in NSCLC was 4.28% (11/257), higher in non-smokers (47.47%, 122/257), and higher in RRM1 mRNA Accounting for 61.87% (159/257). The positive expression of EML4-ALK fusion gene was not related to the expression of ERCC1 mRNA in NSCLC patients without positive EML4-ALK fusion gene expression (P> 0.05). The positive expression of EML4-ALK fusion gene in NSCLC tissues was not related to the expression of RRM1 mRNA P> 0.05). However, the expression of ERCC1 mRNA was correlated with the expression of RRM1 mRNA (P <0.05). CONCLUSIONS: Patients with positive EML4-ALK fusion gene in NSCLC tissues can not benefit from first-line platinum and other chemotherapeutic agents. Therefore, it is still necessary to explore more effective individualized treatment regimens, especially for EML4-ALK fusion gene Inhibitor crizotinib primary or secondary resistant part of the patient’s individualized treatment.